Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 26;12:10153–10163. doi: 10.2147/OTT.S223668

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Liu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Correlation of HELLS expression with clinical significance and prognosis in colorectal cancer. (A) Scatter plot analysis of the relative expression of HELLS mRNA in tumor tissues at different T stages. HELLS was upregulated in stage 3/4 (right, n=91) vs stage 1/2 (left, n=19), p=0.0027. (B) The relative expression of HELLS mRNA in tumor tissues at different N stages. The expression for group N 0 (n=70) showed no significant difference with group N 1–2 (n=40). N.O indicates no significant difference. (C) The relative expression of HELLS mRNA in tumor tissues for different M stages. The M 1 group (n=94) had upregulated HELLS expression compared with that of the M 0 group (n=16), p=0.0119. (D) The relative expression of HELLS mRNA in tumor tissues t different clinical TNM stages. The stage III/IV (n=47) group had increased HELLS expression compared with that of stage I/II (n=63), p = 0.0312. The TNM stage determined was according to the UICC/AJCC TNM staging system (8th edition). (E) The relative expression of HELLS mRNA in tumor tissues with nerve infiltration (n=90) or without nerve infiltration (n=20), N.O. (F) Pathological grade reversely correlated with HELLS expression (G1 vs G3), p=0.049. The tumor samples were of various grades (low, low-intermediate, intermediate, intermediate-high, and high grade), as determined by pathologists. Low- and low-intermediate grades were clustered in G1, intermediate in G2, and intermediate-high and high grades in G3. (G) Representative images of immunostained HELLS in tumor tissue and peritumoral tissue. (H) Representative images of stained HELLS in tumor tissue showing distinct intensity. (I) The Kaplan-Meier survival curve for overall survival. Statistics were evaluated by the p log rank test. The follow-up time was 2 years; intense staining of HELLS (n=25) shows poor overall survival compared with the less intensely stained HELLS (n=28); the log-rank p value = 0.027. *p < 0.05, **p < 0.01.